A natural product phillygenin suppresses osteosarcoma growth and metastasis by regulating the SHP-1/JAK2/STAT3 signaling
Authors:
Open Access
- 9 January 2021
- journal article
- research article
- Published by Taylor & Francis in Bioscience, Biotechnology, and Biochemistry
- Vol. 85 (2) , 307-314
Abstract
Osteosarcoma represents one of the most devastating cancers due to its high metastatic potency and fatality. Osteosarcoma is insensitive to traditional chemotherapy. Identification of a small molecule that blocks osteosarcoma progression has been a challenge in drug development. Phillygenin, a plant-derived tetrahydrofurofuran lignin, has shown to suppress cancer cell growth and inflammatory response. However, how phillygenin plays functional roles in osteosarcoma has remained unveiled. In this study, we showed that phillygenin inhibited osteosarcoma cell growth and motility in vitro. Further mechanistic studies indicated that phillygenin blocked STAT3 signaling pathway. Phillygenin led to significant downregulation of Janus kinase 2 and upregulation of Src homology region 2 domain-containing phosphatase 1. Gene products of STAT3 regulating cell survival and invasion were also inhibited by phillygenin. Therefore, our studies provided the first evidence that phillygenin repressed osteosarcoma progression by interfering STAT3 signaling pathway. Phillygenin is a potential candidate in osteosarcoma therapy.Keywords
Funding Information
- National Natural Science Foundation of China (81501866)
- Jiangsu Provincial Medical Youth Talent Foundation (QNRC2016411)
- Jiangsu Six One (LGY2018035)
This publication has 19 references indexed in Scilit:
- Phillygenin Exerts In Vitro and In Vivo Antitumor Effects in Drug-Resistant Human Esophageal Cancer Cells by Inducing Mitochondrial-Mediated Apoptosis, ROS Generation, and Inhibition of the Nuclear Factor kappa B NF-κB Signalling PathwayMedical Science Monitor, 2019
- Phillygenin exhibits anti-inflammatory activity through modulating multiple cellular behaviors of mouse lymphocytesImmunopharmacology and Immunotoxicology, 2019
- Osteosarcoma: Current Treatment and a Collaborative Pathway to SuccessJournal of Clinical Oncology, 2015
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer CellsCancer Cell, 2014
- Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cellsBreast Cancer Research, 2013
- Butein Suppresses Constitutive and Inducible Signal Transducer and Activator of Transcription (STAT) 3 Activation and STAT3-Regulated Gene Products through the Induction of a Protein Tyrosine Phosphatase SHP-1Molecular Pharmacology, 2009
- Caffeic acid and its synthetic derivative CADPE suppress tumor angiogenesis by blocking STAT3-mediated VEGF expression in human renal carcinoma cellsCarcinogenesis, 2007
- Neoadjuvant Chemotherapy With High-Dose Ifosfamide, High-Dose Methotrexate, Cisplatin, and Doxorubicin for Patients With Localized Osteosarcoma of the Extremity: A Joint Study by the Italian and Scandinavian Sarcoma GroupsJournal of Clinical Oncology, 2005
- Targeting Stat3 in cancer therapyAnti-Cancer Drugs, 2005
- Signal transducer and activator of transcription proteins in leukemiasBlood, 2003